YMAB(Delisted)
Y-mAbs TherapeuticsยทNASDAQ
--
--(--)
YMAB fundamentals
Y-mAbs Therapeutics (YMAB) released its earnings on Aug 8, 2025: revenue was 19.53M (YoY -14.34%), beat estimates; EPS was -0.07 (YoY +66.67%), beat estimates.
Revenue / YoY
19.53M
-14.34%
EPS / YoY
-0.07
+66.67%
Report date
Aug 8, 2025
EPS
Revenue
Revenue & Expenses
YMAB has released its 2025 Q2 earnings report, with revenue of 19.52M, reflecting a YoY change of -14.36%, and net profit of -3.24M, showing a YoY change of 64.98%. The Sankey diagram below clearly presents YMAB's revenue sources and cost distribution.
Key Indicators
Y-mAbs Therapeutics (YMAB) key financial stats and ratios, covering profitability, financial health, and leverage.
Y-mAbs Therapeutics (YMAB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Y-mAbs Therapeutics (YMAB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Y-mAbs Therapeutics (YMAB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Y-mAbs Therapeutics (YMAB) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Y-mAbs Therapeutics (YMAB) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
